A Study of LY2940680 in Healthy Participants

Lilly

Status and phase

Completed

Phase 1

Conditions

Healthy Volunteers

Treatments

Drug: [^14C]-LY2940680

Study type

Interventional

Funder types

Industry

Identifiers

NCT01746745

14892

I4J-MC-HHBF (Other Identifier)

Details and patient eligibility

About

This is a single dose study of radiolabelled LY2940680 taken by mouth in healthy participants to study how the body absorbs and removes LY2940680 from the blood. This study is for research purposes only and is not intended to treat any medical condition.

Enrollment

6 patients

Sex

All

Ages

18 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Generally healthy sterile males or surgically sterile females or postmenopausal females, as determined by medical history and laboratory assessments
Have a body mass index (BMI) of 18.5 to 32.0 kilograms per square meter (kg/m^2), inclusive

Exclusion criteria

Regularly use known drugs of abuse and/or show positive findings on urinary drug screening
Have consumed herbal supplements, grapefruit juice, grapefruits, grapefruit containing products, Seville orange juice, Seville oranges, star fruit, or star fruit juice within 7 days prior to dosing or intend to consume during the study
Have donated blood of more than 500 milliliters (mL) within the last month
Have participated in a [^14C]-study within the last 6 months prior to admission for this study
Exposure to significant radiation within 12 months prior to dose (for example, serial X-ray or computed tomography scans, barium meal, current employment in a job requiring radiation exposure monitoring)
Have a pattern less than once per 2 days to expel feces from the bowel through the rectum or acute constipation within 3 weeks of the day prior to dose